Pulmatrix files S-4 for Eos merger as cash falls to $2.2M
What's the deal? Pulmatrix (Nasdaq: PULM) has filed a Form S-4 with the Securities and Exchange Commission for its proposed merger with Eos SENOLYTIXDealroom has a profile for this one. Try Dealroom →, a privately held biotech developing gerotherapeutic peptides that target mitochondrial dysfunction in aging-related diseases. The deal, first announced in March 2026, is expected to close in the third quarter of 2026, subject to customary conditions.
What's the endgame? If completed, Eos's business will continue as the combined company. Pulmatrix, meanwhile, is seeking to out-license or monetize its iSPERSE-based clinical assets — PUR1900, PUR3100 and PUR1800 — with all clinical development currently on hold.
By the numbers: For the second quarter of 2026, Pulmatrix reported research and development expense under $0.1 million, general and administrative costs of $1.0 million, and a net loss of $1.1 million. Cash and equivalents fell to $2.2 million as of June 30, 2026, down from $4.1 million at year-end, with an accumulated deficit of $304.5 million.
Why now? A March 2026 private placement of Series B convertible preferred stock with an Eos affiliate raised $1.0 million in gross proceeds. Pulmatrix says its cash, prepared on a going-concern basis, is expected to fund operations at least through the anticipated merger close.
What could go wrong? The merger remains unclosed, and an amended shelf registration describes up to 490,910 common shares issuable as conversion or dividend shares for resale — potential dilution for existing holders. The company's financial statements carry a going-concern warning within one year.
On the pipeline, Pulmatrix was awarded an Indian patent covering PUR1900 in July 2026, and partner CiplaDealroom has a profile for this one. Try Dealroom → has been cleared to run a Phase 3 trial of the inhaled antifungal in India. Pulmatrix stands to earn 2% royalties on any future net sales by Cipla outside the US.
The signal: The filing marks a familiar path for cash-strapped clinical-stage biotechs — pausing internal development, monetizing legacy assets, and turning to a reverse merger to hand the public shell to a private company with an active pipeline.
Read more: StockTitan
Image credit: National Institutes of Health (NIH)
